These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10671643)

  • 1. Inherited variations in drug-metabolizing enzymes: significance in clinical oncology.
    Iyer L
    Mol Diagn; 1999 Dec; 4(4):327-33. PubMed ID: 10671643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
    Bosch TM
    Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics: a tool for individualizing antineoplastic therapy.
    Innocenti F; Iyer L; Ratain MJ
    Clin Pharmacokinet; 2000 Nov; 39(5):315-25. PubMed ID: 11108431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.
    Candelaria M; Taja-Chayeb L; Arce-Salinas C; Vidal-Millan S; Serrano-Olvera A; Dueñas-Gonzalez A
    Anticancer Drugs; 2005 Oct; 16(9):923-33. PubMed ID: 16162969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.
    Quaranta S; Thomas F
    Therapie; 2017 Apr; 72(2):205-215. PubMed ID: 28262261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents.
    Sekine I; Saijo N
    Ann Oncol; 2001 Nov; 12(11):1515-25. PubMed ID: 11822749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics and cancer chemotherapy.
    Iyer L; Ratain MJ
    Eur J Cancer; 1998 Sep; 34(10):1493-9. PubMed ID: 9893619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomic applications in oncology.
    Walko CM; Ikediobi O
    J Pharm Pract; 2012 Aug; 25(4):439-46. PubMed ID: 22907843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer pharmacogenomics: current and future applications.
    Watters JW; McLeod HL
    Biochim Biophys Acta; 2003 Mar; 1603(2):99-111. PubMed ID: 12618310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug metabolizing enzymes and their inhibitors' role in cancer resistance.
    Pathania S; Bhatia R; Baldi A; Singh R; Rawal RK
    Biomed Pharmacother; 2018 Sep; 105():53-65. PubMed ID: 29843045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
    Hasegawa Y
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):325-33. PubMed ID: 12669388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics of cancer chemotherapy-induced toxicity.
    Miller CR; McLeod HL
    J Support Oncol; 2007 Jan; 5(1):9-14. PubMed ID: 17265780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
    Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
    Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics and individualized drug therapy.
    Eichelbaum M; Ingelman-Sundberg M; Evans WE
    Annu Rev Med; 2006; 57():119-37. PubMed ID: 16409140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
    Maitland ML; Vasisht K; Ratain MJ
    Trends Pharmacol Sci; 2006 Aug; 27(8):432-7. PubMed ID: 16815558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of thiopurine S-methyltransferase gene polymorphisms.
    Mladosievicova B; Dzurenkova A; Sufliarska S; Carter A
    Neoplasma; 2011; 58(4):277-82. PubMed ID: 21520983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalizing chemotherapy dosing using pharmacological methods.
    Patel JN; Papachristos A
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):879-96. PubMed ID: 26298089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of cytotoxic drugs.
    Daly AK; Hall AG
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):301-8. PubMed ID: 12113035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.